The overall objective of this task order is to evaluate preclinical efficacy of the following agents targeting various pathways in preventing esophageal cancer in L2-IL-1beta mouse model of Barrett’s esophagus. Barrett's esophagus (BE), a condition in which the extent of metaplastic columnar epithelium that predisposes to cancer development replaces the stratified squamous epithelium, occurs in the in the distal esophagus. BE is diagnosed endoscopically using high-definition video endoscopy, and it has been known as a premalignant condition for the development of esophageal cancer. Gastroesophageal reflux diseases (GERD), abdominal obesity, hypergastrinemia, cigarette smoking, carcinogen exposure, diet, and lifestyle are important risk factors for Barrett’s esophagus and its associated carcinoma. The risk of progression to esophageal cancer increases with the length of the Barrett’s esophagus.